MA46570B1 - Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t - Google Patents

Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Info

Publication number
MA46570B1
MA46570B1 MA46570A MA46570A MA46570B1 MA 46570 B1 MA46570 B1 MA 46570B1 MA 46570 A MA46570 A MA 46570A MA 46570 A MA46570 A MA 46570A MA 46570 B1 MA46570 B1 MA 46570B1
Authority
MA
Morocco
Prior art keywords
clec
promoting
methods
lymphocytes
reaction
Prior art date
Application number
MA46570A
Other languages
English (en)
Other versions
MA46570A (fr
Inventor
Nicolas Poirier
Bernard Vanhove
Vanessa Gauttier
Elise Chiffoleau
Géraldine TEPPAZ
Original Assignee
Ose Immunotherapeutics
Inst Nat Sante Rech Med
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics, Inst Nat Sante Rech Med, Univ Nantes filed Critical Ose Immunotherapeutics
Publication of MA46570A publication Critical patent/MA46570A/fr
Publication of MA46570B1 publication Critical patent/MA46570B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes pour favoriser la réponse des lymphocytes t. Les inventeurs ont examiné l'expression et la fonction de clec-1 dans des cd humaines et démontré pour la première fois une expression de surface cellulaire. Ils ont étudié son rôle fonctionnel suite à un déclenchement sur l'orchestration des réponses des lymphocytes t. Les inventeurs ont montré in vitro et in vivo avec des rats déficients en clec-1 et une protéine de fusion clec-1 fc de rat que la perturbation de la signalisation de clec-1 améliore l'activation de th17 in vitro et améliore in vivo l'amorçage des lymphocytes t et l'activation de th17 et th1. En particulier, la présente invention concerne des antagonistes de clec-1 pour favoriser la réponse des lymphocytes t chez un sujet en ayant besoin.
MA46570A 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t MA46570B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP17305988 2017-07-24
PCT/EP2017/076911 WO2018073440A1 (fr) 2016-10-21 2017-10-20 Procédés pour favoriser la réponse des lymphocytes t

Publications (2)

Publication Number Publication Date
MA46570A MA46570A (fr) 2021-03-31
MA46570B1 true MA46570B1 (fr) 2021-10-29

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46570A MA46570B1 (fr) 2016-10-21 2017-10-20 Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t

Country Status (21)

Country Link
US (3) US11365257B2 (fr)
EP (2) EP3529262B1 (fr)
JP (2) JP7032396B6 (fr)
KR (1) KR102646708B1 (fr)
CN (1) CN110291102A (fr)
AU (1) AU2017345286B2 (fr)
CA (1) CA3039348C (fr)
CY (1) CY1124584T1 (fr)
DK (1) DK3529262T3 (fr)
ES (2) ES2883678T3 (fr)
HR (1) HRP20211544T1 (fr)
HU (1) HUE056016T2 (fr)
IL (1) IL266111B (fr)
LT (1) LT3529262T (fr)
MA (1) MA46570B1 (fr)
MD (1) MD3529262T2 (fr)
PL (1) PL3529262T3 (fr)
RS (1) RS62463B1 (fr)
SI (1) SI3529262T1 (fr)
SM (1) SMT202100555T1 (fr)
WO (1) WO2018073440A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3529262T3 (pl) * 2016-10-21 2021-12-27 Inserm - Institut National De La Santé Et De La Recherche Médicale Sposoby wspomagania odpowiedzi limfocytów t
IL268895B2 (en) 2017-02-28 2025-05-01 Vor Biopharma Inc Compositions and methods for inhibition of lineage specific proteins
WO2020047164A1 (fr) 2018-08-28 2020-03-05 Vor Biopharma, Inc Cellules souches hématopoïétiques génétiquement modifiées et utilisations associées
CA3159155A1 (fr) * 2019-12-05 2021-06-10 Ose Immunotherapeutics Anticorps anti-clec-1 a et fragment de liaison a l'antigene de ceux-ci
CN113156140A (zh) * 2021-03-05 2021-07-23 青岛大学附属医院 C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用
US12448454B2 (en) 2021-06-08 2025-10-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof
CN118510534A (zh) 2021-11-09 2024-08-16 Ose免疫疗法 Clec-1配体的识别及其用途
WO2024028347A1 (fr) 2022-08-01 2024-02-08 Ose Immunotherapeutics Molécule hybride fc-clec-1 hétérodimère et ses utilisations
WO2025032213A1 (fr) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification d'hla-dra en tant que ligand de clec-1 et ses utilisations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
WO1995002420A2 (fr) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Bioprecurseurs d'inhibiteurs de la tyrosine-kinase de proteines
EP0690452A3 (fr) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Mémoire électriquement effaçable et procédé d'effacement
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000207A1 (fr) 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la src kinase
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
KR100681724B1 (ko) 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
JP2003512353A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002346053B2 (en) 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003011836A1 (fr) 2001-08-01 2003-02-13 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US8246959B1 (en) * 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2717656A1 (fr) * 2007-02-23 2008-08-28 Baylor Research Institute Activation de cellules humaines presentant un antigene par l'intermediaire de clec-6
JP5641508B2 (ja) * 2010-02-23 2014-12-17 国立大学法人 東京大学 樹状細胞免疫受容体刺激剤
JP6736540B2 (ja) * 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
PL3529262T3 (pl) 2016-10-21 2021-12-27 Inserm - Institut National De La Santé Et De La Recherche Médicale Sposoby wspomagania odpowiedzi limfocytów t

Also Published As

Publication number Publication date
SMT202100555T1 (it) 2021-11-12
JP2022065159A (ja) 2022-04-26
CN110291102A (zh) 2019-09-27
CA3039348A1 (fr) 2018-04-26
EP3950709A1 (fr) 2022-02-09
MD3529262T2 (ro) 2022-01-31
EP3950709B1 (fr) 2024-02-14
JP7404418B2 (ja) 2023-12-25
JP7404418B6 (ja) 2024-01-26
US20220281983A1 (en) 2022-09-08
WO2018073440A1 (fr) 2018-04-26
US20190309075A1 (en) 2019-10-10
IL266111B (en) 2022-09-01
IL266111A (en) 2019-06-30
JP2020503252A (ja) 2020-01-30
AU2017345286A1 (en) 2019-04-18
EP3529262B1 (fr) 2021-07-21
HUE056016T2 (hu) 2022-01-28
US12091464B2 (en) 2024-09-17
HRP20211544T1 (hr) 2022-01-07
LT3529262T (lt) 2021-11-10
CY1124584T1 (el) 2022-07-22
KR102646708B1 (ko) 2024-03-12
JP7032396B2 (ja) 2022-03-08
KR20190068605A (ko) 2019-06-18
EP3529262A1 (fr) 2019-08-28
SI3529262T1 (sl) 2021-12-31
CA3039348C (fr) 2023-09-05
ES2978486T3 (es) 2024-09-13
PL3529262T3 (pl) 2021-12-27
US11365257B2 (en) 2022-06-21
RS62463B1 (sr) 2021-11-30
AU2017345286B2 (en) 2023-08-03
US20240400695A1 (en) 2024-12-05
MA46570A (fr) 2021-03-31
JP7032396B6 (ja) 2022-03-22
DK3529262T3 (da) 2021-09-20
ES2883678T3 (es) 2021-12-09

Similar Documents

Publication Publication Date Title
Toren et al. Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis
Syed et al. PAHSAs attenuate immune responses and promote β cell survival in autoimmune diabetic mice
Chapman et al. mTOR signaling, Tregs and immune modulation
Clarke et al. B1a B cells require autophagy for metabolic homeostasis and self-renewal
Wang et al. De novo generation and enhanced suppression of human CD4+ CD25+ regulatory T cells by retinoic acid
Pittet et al. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression
Meuth et al. Cytotoxic CD8+ T cell–neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death
Delpoux et al. Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8+ T cells
Soares et al. Regulated vesicle fusion generates signaling nanoterritories that control T cell activation at the immunological synapse
Fu et al. Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation
Zhang et al. Migratory and adhesive cues controlling innate-like lymphocyte surveillance of the pathogen-exposed surface of the lymph node
Sanchez-Correa et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
Casado et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype
Cornwell et al. Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques
Do et al. Nutrient mTORC1 signaling underpins regulatory T cell control of immune tolerance
Harper et al. Dynamic resolution of acrosomal exocytosis in human sperm
CY1124584T1 (el) Μεθοδοι προωθησης της αποκρισης τ κυτταρων
Vacher-Coponat et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients
Kahaly et al. Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin
Jeanty et al. HLA–B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis
Schuldt et al. Cutting edge: Dual TCRα expression poses an autoimmune hazard by limiting regulatory T cell generation
Lucas et al. Control of the thymic medulla and its influence on αβT‐cell development
Vocanson et al. Human T cell priming assay: Depletion of peripheral blood lymphocytes in CD25+ cells improves the in vitro detection of weak allergen-specific T cells
Maslarova et al. Increased susceptibility to acetylcholine in the entorhinal cortex of pilocarpine-treated rats involves alterations in KCNQ channels
Choe et al. In vivo high spatiotemporal resolution visualization of circulating T lymphocytes in high endothelial venules of lymph nodes